Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9787159 | 1.00 | DPP4 (0.55) | DPP4PLA2G10PLA2G2APARP10HSD17B10 | |
| SCHEMBL9684230 | 1.00 | DPP4 (0.55) | DPP4PLA2G10PLA2G2APARP10HSD17B10 | |
| Hydrochloric Acid SCHEMBL11467261 | 0.98 | DPP4 (0.54) | DPP4PLA2G10PLA2G2APARP10HSD17B10 | |
| Hydrochloric Acid SCHEMBL10561063 | 0.98 | DPP4 (0.54) | DPP4PLA2G10PLA2G2APARP10HSD17B10 | |
| SCHEMBL8293310 | 0.87 | DPP4 (0.56) | DPP4PLA2G10PLA2G2APARP10HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL11119550 | 0.85 | DPP4 (0.55) | DPP4PLA2G10PLA2G2APARP10HSD17B10 | |
| SCHEMBL825507 | 0.85 | ALDH1A1 (0.52) | DPP4MEN1HTTKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL825805 | 0.84 | ALDH1A1 (0.50) | DPP4MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL9392575 | 0.81 | TAAR1 (0.59) | PLA2G10PLA2G2A | |
| SCHEMBL6764390 | 0.81 | TAAR1 (0.59) | PLA2G10PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20020165234-A1 | Selective B3 adrenergic agonists | CROWELL THOMAS A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-0827746-B1 | Carbazole analogues as selective beta3 adrenergic agonists | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0827746-A1 | Carbazole analogues as selective B3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5166218-A | Antilipemic agents or antiglycemic agents | HOFFMANN-LA ROCHE INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-4871755-A | Method for treating diabetes obesity and conditions characterized by increased protein breakdown with novel oxazolidines | HOFFMANN-LA ROCHE INC. (US) | 1989-10-03 | — | — | US | disclosed |
| US-4845127-A | ANTIBESITY | ELI LILLY AND COMPANY (US) | 1989-07-04 | — | — | US | disclosed |
| US-4743604-A | ANTIBESITY, ANTIDIABETIC, FEEDS | HOFFMANN-LA ROCHE INC. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0104888-B1 | PROCESS FOR PREPARING 2-HYDROXY-2-PHENYLETHYLAMINES | ELI LILLY AND COMPANY (US) | 1986-10-15 | — | — | EP | disclosed |
| EP-0101069-B1 | PHENETHANOL AMINES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-04-23 | — | — | EP | disclosed |
| EP-0170121-A1 | 2-Hydroxy-3-aryloxypropyl or 2-hydroxy-2-benzofuranyl ethyl tertiary amine having an anti-hyperglycaemic and/or anti-obesity activity | BEECHAM GROUP PLC (GB) | 1986-02-05 | — | — | EP | disclosed |
| EP-0151513-A1 | Inotropic agent | ELI LILLY AND COMPANY (US) | 1985-08-14 | — | — | EP | disclosed |
| EP-0140243-A2 | Phenoxypropanol amines | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-05-08 | — | — | EP | disclosed |
| EP-0104888-A1 | Process for preparing 2-hydroxy-2-phenylethylamines | ELI LILLY AND COMPANY (US) | 1984-04-04 | — | — | EP | disclosed |
| EP-0101069-A1 | Phenethanol amines | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | DPP4 577/4885PLA2G10 3450/4885PLA2G2A 2857/4885 |
| US-20020165234-A1 | Selective B3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | DPP4 344/4885PLA2G10 2475/4885PLA2G2A 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.